ClinicalTrials.gg
TerminatedNCT01335997Updated Feb 6, 2019Results posted

Efficacy and Safety of Extended-Release Niacin/ Laropiprant/Simvastatin Tablets in Participants With Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-143)

A Phase 3 interventional study of ER niacin/laropiprant (ERN/LRPT) and ER niacin/laropiprant/simvastatin (ERN/LRPT/SIM) in Primary Hypercholesterolemia and Mixed Dyslipidemia, sponsored by Merck Sharp & Dohme LLC. Terminated. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2019-02-06.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

Why this study was terminated
Business Reasons

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,139
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 50 studies testing simvastatin in Hypercholesterolemia — none open to participants now, none under way, none of them phase 3. Simvastatin · Hypercholesterolemia.

Enrollment
6th of 49
1,139 · median 240
Started
2011
with 1 other
Phase 3
26 of 50
none open now
Registered
42nd of 50
by date
Lead sponsor
3 of 50
Merck Sharp & Dohme LLC

Among the 50 studies testing simvastatin in Hypercholesterolemia, this one is the 6th largest by enrollment of the 49 interventional ones that give a count, is one of 2 that started in 2011, is one of 26 in phase 3, and was the 42nd registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

None of the 50 studies testing simvastatin in Hypercholesterolemia is open now. The open studies under Hypercholesterolemia, anywhere →

About simvastatin

Simvastatin: first FDA approval 1991 (ZOCOR), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 50 studies testing simvastatin in Hypercholesterolemia as a file.
02

Study summary

This study is being done to find out if tablets containing extended release (ER) niacin, laropiprant, and simvastatin (ERN/LRPT/SIM) are as effective as tablets containing ER niacin and laropiprant taken with simvastatin tablets (ERN/LRPT + SIM) for lowering high cholesterol and high lipid levels in the blood. The primary hypothesis is that ERN/LRPT/SIM 2 g /20 mg is equivalent to ERN/LRPT 2 g coadministered with simvastatin 20 mg in reducing low-density lipoprotein cholestrol (LDL-C).

03

Conditions studied

  • Primary Hypercholesterolemia
  • Mixed Dyslipidemia

Keywords

  • Low-density lipoprotein
  • LDL
  • High-density lipoprotein
  • HDL
  • Niacin
  • Lipid modifying therapy
  • Cholesterol
  • High cholesterol
  • Triglycerides
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has a history of primary hypercholesterolemia or mixed dyslipidemia and meets LDL-C and triglyceride criteria.
  • Is high risk coronary heart disease (CHD) and has LDL-C ≤190 mg/dL (≤4.91 mmol/L).
  • Is not high risk CHD and has LDL-C ≤240 mg/dL (≤6.21 mmol/L).

Exclusion criteria

Exclusion criteria:

  • Is pregnant or breast-feeding, or expecting to conceive or donate eggs or sperm during the study.
  • Has a history of within ≤5 years, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
  • Consumes more than 3 alcoholic drinks per day (14 per week).
  • Is a high risk CHD patient on lipid modifying therapy (LMT).
  • Is on any LMT with equivalent or greater LDL-C-lowering efficacy than simvastatin 40 mg.
  • Has Type 1 or Type 2 diabetes mellitus that is poorly controlled, or on statin therapy.
  • Currently engages in vigorous exercise or is on an aggressive diet regimen.
  • Has uncontrolled endocrine or metabolic disease, uncontrolled gout, kidney or hepatic disease, heart failure, recent peptic ulcer disease, or allergic reaction to niacin or simvastatin, recent heart attack, stroke or heart surgery.
  • Is (HIV) positive.
  • Has taken niacin >50 mg/day, bile-acid sequestrants, 3-hydroxy-3-methylglutaryl-coenzyme A(HMG-CoA) reductase inhibitors, ezetimibe, Cholestin™ [red yeast rice] and other red yeast products within 6 weeks, or fibrates within 8 weeks of randomization visit (Visit 3).

Note: Fish oils, phytosterol margarines and other non-prescribed therapies are allowed provided participant has been on a stable dose for 6 weeks prior to Visit 2 and agrees to remain on this dose for the duration of the study.

  • Is currently receiving cyclical hormonal or intermittent use of hormone replacement therapies (HRTs) (e.g., estradiol, medroxyprogesterone, progesterone). Note: Participants who have been on a stable dose of non-cyclical HRT or hormonal contraceptive for greater than 6 weeks prior to Visit 1 are eligible if they agree to remain on the same regimen for the duration of the study.
  • Is taking prohibited medications such as systemic , potent inhibitors of Cytochrome P450 3A4 (), cyclosporine, danazol, or fusidic acid.
  • Consumes >1 quart of grapefruit juice/day.
  • Requires warfarin treatment and has not been on a stable dose with a stable (INR) for at least 6 weeks prior to Visit 1.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
1,139 participants (actual)

Study arms

  • Experimental
    ERN/LRPT/SIM → ERN/LRPT+SIM

    Weeks 0-4 (Period 1): Participants will take ERN/LRPT/SIM 1 g/10 mg and SIM-matching placebo tablets daily; Weeks 5-12 (Period 2): Participants will be advanced to ERN/LRPT/SIM 2 g/20 mg and SIM-matching placebo tablets daily; Weeks 13-20 (Period III): Participants will crossover to ERN/LRPT 2 g + SIM 20 mg coadministration treatment.

    Drug: ER niacin/laropiprant (ERN/LRPT) · Drug: ER niacin/laropiprant/simvastatin (ERN/LRPT/SIM) · Drug: Simvastatin (SIM) · Drug: Placebo Run-In · Drug: SIM-matching placebo

  • Active comparator
    ERN/LRPT+SIM → ERN/LRPT/SIM

    Weeks 0-4 (Period I): Participants will take ERN/LRPT co-administered with SIM (ERN/LRPT 1g + SIM 10 mg tablets) daily; Weeks 5-12 (Period II): Participants will be advanced to ERN/LRPT 2 g + SIM 20 mg daily; Weeks 13-20 (Period III): Participants will crossover to the ERN/LRPT/SIM 2 g/20 mg combination treatment and SIM-matching placebo tablets.

    Drug: ER niacin/laropiprant (ERN/LRPT) · Drug: ER niacin/laropiprant/simvastatin (ERN/LRPT/SIM) · Drug: Simvastatin (SIM) · Drug: Placebo Run-In · Drug: SIM-matching placebo

Interventions

  • DrugER niacin/laropiprant (ERN/LRPT)

    Drug page: MK-0524B

    ER niacin 1 g/laropiprant 20 mg oral tablet taken once daily

    Also known as: MK-0524B

  • DrugER niacin/laropiprant/simvastatin (ERN/LRPT/SIM)

    ER niacin 1 g/laropiprant 20 mg/simvastatin 10 mg oral tablet taken once daily

    Also known as: MK-0524A, Tredaptive™

  • Simvastatin 10 mg oral tablet taken once daily

    Also known as: Zocor®

  • DrugPlacebo Run-In

    Placebo matches both ER niacin 1 g/laropiprant 20 mg oral tablet and ER niacin 1 g/laropiprant 20 mg/simvastatin 10 mg oral tablet; placebo is taken once daily

  • DrugSIM-matching placebo

    Placebo for simvastatin 10 mg oral tablet taken once daily

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) Blood Levels

    Due to study termination caused by the decision to stop the development of the combination tablet, sufficient data were not available to perform the planned efficacy analysis, which is based on the cross-over data collected in period II and III.

    Time frame: Baseline and Week 12 and Week 20

Secondary outcomes

  1. Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C) Blood Levels

    Due to study termination caused by the decision to stop the development of the combination tablet, sufficient data were not available to perform the planned efficacy analysis, which is based on the cross-over data collected in period II and III.

    Time frame: Baseline and Week 12 and Week 20

07

Results

Posted Jun 21, 2016
Limitations and caveats
Study was terminated for business reasons.

Participant flow

Period I and II
Participant flow — Period I and II
MilestoneERN/LRPT/SIM → ERN/LRPT+SIM (Sequence 1)ERN/LRPT+SIM → ERN/LRPT/SIM (Sequence 2)
Started577562
Completed8483
Not completed493479
Withdrew: Adverse event6343
Withdrew: Noncompliance with study drug11
Withdrew: Lost to follow-up35
Withdrew: Withdrawal by subject94
Withdrew: Study terminated by sponsor406415
Withdrew: Protocol violation910
Withdrew: Physician decision21
Period III
Participant flow — Period III
MilestoneERN/LRPT/SIM → ERN/LRPT+SIM (Sequence 1)ERN/LRPT+SIM → ERN/LRPT/SIM (Sequence 2)
Started8483
Completed64
Not completed7879
Withdrew: Adverse event02
Withdrew: Study terminated by sponsor7776
Withdrew: Protocol violation01
Withdrew: Lost to follow-up10

Outcome measures

PrimaryChange From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) Blood Levels

Due to study termination caused by the decision to stop the development of the combination tablet, sufficient data were not available to perform the planned efficacy analysis, which is based on the cross-over data collected in period II and III.

Time frame:
Baseline and Week 12 and Week 20

No measurements were reported for this outcome.

SecondaryChange From Baseline in High Density Lipoprotein Cholesterol (HDL-C) Blood Levels

Due to study termination caused by the decision to stop the development of the combination tablet, sufficient data were not available to perform the planned efficacy analysis, which is based on the cross-over data collected in period II and III.

Time frame:
Baseline and Week 12 and Week 20

No measurements were reported for this outcome.

Adverse events

Collected over Up to 22 weeks, including 14 days after last dose of study drug (non-serious adverse events up to 20 weeks and serious adverse events up to 22 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Seq 1 (Periods I+II): ERN/LRPT/SIMVA → ERN/LRPT+SIMVA—11/567 (1.9%)103/567 (18.2%)
Seq 2 (Periods I+II): ERN/LRPT+SIM → ERN/LRPT/SIM—5/554 (0.9%)95/554 (17.1%)
Seq 1 (Period III): ERN/LRPT/SIMVA → ERN/LRPT+SIMVA—0/83 (0%)0/83 (0%)
Seq 2 (Period III): ERN/LRPT+SIM → ERN/LRPT/SIM—1/82 (1.2%)0/82 (0%)
Most frequent serious events
Showing 10 of 20
Most frequent serious events
EventSeq 1 (Periods I+II): ERN/LRPT/SIMVA → ERN/LRPT+SIMVASeq 2 (Periods I+II): ERN/LRPT+SIM → ERN/LRPT/SIMSeq 1 (Period III): ERN/LRPT/SIMVA → ERN/LRPT+SIMVASeq 2 (Period III): ERN/LRPT+SIM → ERN/LRPT/SIM
Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/5670/5540/831/82
FlushingVascular disorders1/5672/5540/830/82
Arteriospasm coronaryCardiac disorders0/5671/5540/830/82
Coronary artery diseaseCardiac disorders0/5671/5540/830/82
Thyroid cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/5671/5540/830/82
Angina pectorisCardiac disorders1/5670/5540/830/82
Abdominal discomfortGastrointestinal disorders1/5670/5540/830/82
Gastrointestinal disorderGastrointestinal disorders1/5670/5540/830/82
Non-cardiac chest painGeneral disorders1/5670/5540/830/82
PneumoniaInfections and infestations1/5670/5540/830/82
Most frequent other events
Most frequent other events
EventSeq 1 (Periods I+II): ERN/LRPT/SIMVA → ERN/LRPT+SIMVASeq 2 (Periods I+II): ERN/LRPT+SIM → ERN/LRPT/SIMSeq 1 (Period III): ERN/LRPT/SIMVA → ERN/LRPT+SIMVASeq 2 (Period III): ERN/LRPT+SIM → ERN/LRPT/SIM
FlushingVascular disorders78/56772/5540/830/82
PruritusSkin and subcutaneous tissue disorders39/56729/5540/830/82

Baseline characteristics

Age, Continuous
Age, Continuous(Years)ERN/LRPT/SIM → ERN/LRPT+SIM (Sequence 1)ERN/LRPT+SIM → ERN/LRPT/SIM (Sequence 2)Total
Mean56.2 ± 10.4456.4 ± 10.4456.3 ± 10.43
Sex: Female, Male
Sex: Female, Male(Participants)ERN/LRPT/SIM → ERN/LRPT+SIM (Sequence 1)ERN/LRPT+SIM → ERN/LRPT/SIM (Sequence 2)Total
Female345332677
Male232230462
08

Study locations

No study locations are listed for this record.

09

References and documents

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2011 to primary completion in Jan 2012, 8 months.

Results were first posted in Jun 2016, 4 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 13, 2011
First posted
Apr 15, 2011
StartActual
May 1, 2011
Primary completionActual
Jan 1, 2012
CompletionActual
Jan 1, 2012
Results first posted
Jun 21, 2016
Last update
Feb 6, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 6, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01335997
Responsible party
Sponsor
First posted
Apr 15, 2011
Start date
May 1, 2011
Primary completion
Jan 1, 2012
Completion
Jan 1, 2012
Results posted
Jun 21, 2016
Last update
Feb 6, 2019

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: MK-0524B · Simvastatin

Start the discussion